Loading Events

« All Events

  • This event has passed.

Breast Cancer: The Triple Negative Paradox – PERMIDES Digital Health Forum


 (c) Oslo Cancer Cluster

Breast Cancer: The Triple Negative Paradox

Event Details

Triple-negative breast cancer (sometimes abbreviated TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) and Her2/neu. This makes it more difficult to treat since most hormone therapies target one of the three receptors, so triple-negative cancers often require combination therapies.

The symposium will focus on drug discovery, biomarkers and treatment aspects of TNBC. Participants will gain a broad exposure to the fundamental mechanisms driving TNBC through presentations from three speakers discussing the recent advances in this cancer subtype. The Networking session at the end of the symposium will focus on Horizon 2020 funding opportunities for both academia and industry in the field of cancer and personalised medicine.


This event is FREE to attend and you can send your registration by filling the form at the end of this page.

Draft Agenda 

09:00–09:15 Registration and Light Refreshments
09:15–09:30 Welcome and Introduction
09:30–10:10 Development of Small Molecule Anti-Metastatic Agents for Potential Treatment of Triple Negative Breast CancerProf. Andrew Westwell, Cardiff University, United Kingdom
10:10–10:50 New Prognostic Biomarkers for Triple Negative Breast CancerProf. Emiel Janssen, Stavanger University Hospital, Norway 
10:50–11:30 Glyco-TROLL – Innovative treatment for (highly) glycolytic cancersDr. Claudia Bøen, Arctic Pharma AS, Norway
11:30–12:30 Networking Session: Horizon 2020 – Cancer and Personalised MedicineDr. Gupta Udatha, Oslo Cancer Cluster

Information about Symposium Breast Cancer: The Triple Negative Paradox – PERMIDES Digital Health Forum

Symposium Breast Cancer – Digital Health Forum – For notice board

The meeting is supported and arranged in co-operation with:


Jónas Einarsson Auditorium, Oslo Cancer Cluster Innovation Park
Ullernchauseen 64/66 (Entrance 2B)
Oslo, 0379 Norway
+ Google Map